Show simple item record

dc.creatorAbdool Karim, Salim Safurdeen.
dc.creatorBaxter, Cheryl.
dc.date.accessioned2012-11-28T13:13:55Z
dc.date.available2012-11-28T13:13:55Z
dc.date.created2012
dc.date.issued2012
dc.identifier.citationAbdool Karim, S.S., Baxter, C. 2012. Overview of microbicides for the prevention of human immunodeficiency virus. Best Practice & Research Clinical Obstetrics and Gynaecology. 26 (4), pp. 427-439.en
dc.identifier.issn1521-6934
dc.identifier.urihttp://dx.doi.org/10.1016/j.bpobgyn.2012.01.010en
dc.identifier.urihttp://hdl.handle.net/10413/8035
dc.description.abstractHuman immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four classes of candidate microbicides have been tested to date: those that (1) enhance the natural defences in the vagina to inactivate HIV; (2) inactivate HIV in the vagina; (3) prevent HIV from attaching to, and fusing with, the host cells; and (4) prevent HIV from replicating in genital tract host cells. Despite numerous disappointing efficacy trial results over the past 20 years, substantial progress is now being made in microbicide development after the release of the CAPRISA 004 trial, which provided proof-of-concept that topical antiretroviral microbicides can prevent sexual transmission of HIV and herpes simplex type-2 infection. Microbicides, which fill an important gap for women-controlled prevention methods, have the potential to alter the course of the HIV pandemic.en
dc.language.isoenen
dc.publisherElsevier.en
dc.subjectHIV infections--Prevention.en
dc.subjectAntiviral agents.en
dc.subject.otherMicrobicides.en
dc.titleOverview of microbicides for the prevention of human immunodeficiency virus.en
dc.typePeer reviewed journal articleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record